サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1562379

北米のサルコペニア治療：2030年市場予測- 地域別分析- 治療タイプ別、流通チャネル別

North America Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type and Distribution Channel

出版日
ページ情報
英文 72 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
北米のサルコペニア治療：2030年市場予測- 地域別分析- 治療タイプ別、流通チャネル別
出版日: 2024年07月04日
発行: The Insight Partners
ページ情報: 英文 72 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米のサルコペニア治療市場は、2022年に14億5,112万米ドルと評価され、2030年には22億7,385万米ドルに達すると予測され、2022～2030年のCAGRは5.8%と推定されます。

高齢者人口の増加が北米のサルコペニア治療市場を活性化

高齢者人口はサルコペニア、整形外科疾患、代謝疾患、神経疾患などに罹患しやすいです。サルコペニアは、骨格筋の質量と強度の進行性低下を特徴とする高齢者病です。サルコペニアは、転倒、障害、施設入所、生活の質の低下、死亡など、健康上の好ましくない結果をもたらすリスクが高いです。先進諸国では高齢者人口が急速に増加しています。世界保健機関（WHO）によると、世界の高齢化人口は2019年の10億人から2050年には21億人に増加すると見られています。また、2020年の国勢調査によると、米国の65歳以上の人口は、1920～2020年までの100年間に総人口の約5倍の速さで増加しました。2020年には、高齢者人口は5,580万人に達し、米国総人口の16.8％を占める。

加齢は、体組成の大きな変化の一つとして筋肉量の減少をもたらします。高齢者の食物摂取量の著しい減少は、筋肉量の減少を引き起こす重要な要因の一つです。米国国立医療図書館によると、50～60歳の人は毎年1.5％近く筋力が低下し、60歳以降は毎年1～2％の筋肉量が低下するといいます。一般集団に比べ、高齢者はサルコペニアの有病率が高いです。2023年6月にElsevier誌に発表された論文によると、サルコペニアの有病率は糖尿病患者の18％から難治性食道がん患者の66％に及びます。したがって、高齢者人口の増加はサルコペニア治療市場の成長に大きく寄与しています。

北米のサルコペニア治療市場概要

北米のサルコペニア治療市場は米国、カナダ、メキシコに区分されます。北米は2022年の世界市場で最大のシェアを占めています。北米におけるサルコペニア治療市場の成長は、治療のための栄養補助食品の採用が増加していることに起因しています。また、高齢者人口におけるビタミンB12とビタミンD欠乏症の症例数の増加とともに、整形外科疾患の有病率が急上昇していることも、この地域の市場を後押ししています。

サルコペニアの有病率は年齢や性別によって異なり、米国では福祉施設やコミュニティで生活する高齢者がこの症状を発症するリスクが高いです。米国国立衛生研究所によると、2019年に予想されるサルコペニア患者の入院費は404億米ドルです。サルコペニアの人は、筋肉量と機能が正常な人に比べ、毎年平均で2,315米ドル多く通院費を支払っており、サルコペニアでない人に比べ、入院する確率は約2倍です。さらに、骨格筋の減少が10％減少すれば、サルコペニアの合併症を予防でき、米国の年間医療費を約10億米ドル節約できます。

北米のサルコペニア治療市場の収益と2030年までの予測（金額）

北米のサルコペニア治療市場のセグメンテーション

北米のサルコペニア治療市場は、治療タイプ、流通チャンネル、国に分類されます。

治療タイプ別に見ると、北米のサルコペニア治療市場はビタミンDとカルシウムサプリメント、タンパク質サプリメント、ビタミンB12サプリメント、その他に区分されます。2022年の北米のサルコペニア治療市場シェアは、ビタミンD・カルシウムサプリメントセグメントが最大でした。

流通チャンネルでは、北米のサルコペニア治療市場は薬局、小売チャンネル、オンラインチャンネル、その他に区分されます。2022年の北米のサルコペニア治療市場シェアは薬局セグメントが最大でした。

国別では、北米のサルコペニア治療市場は米国、カナダ、メキシコに区分されます。2022年の北米のサルコペニア治療市場シェアは米国が独占しました。

Abbott Laboratories、Bayer AG、Metagenics LLC、Nestle Health Science SA、Novartis AG、Pfizer Inc、Sanofi SA、Amway Corp、GSK Plc、Makers Nutrition LLCは、北米のサルコペニア治療市場で事業を展開する主要企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米のサルコペニア治療市場-主要産業力学

  • 北米のサルコペニア治療市場：主要産業力学
  • 市場促進要因
    • 高齢者人口の増加
    • 成人における栄養不良とビタミン欠乏症の増加
  • 主要市場抑制要因
    • 直接的な治療法の入手不可能性
  • 主要市場機会
    • 臨床試験段階の製品
  • 今後の動向
    • サルコペニアに対する意識の高まり
  • 促進要因と抑制要因の影響

第5章 サルコペニア治療市場：北米市場分析

  • 北米のサルコペニア治療市場収益（2020～2030年）
  • 北米のサルコペニア治療市場の予測と分析

第6章 北米のサルコペニア治療市場分析-治療タイプ別

  • ビタミンDとカルシウムサプリメント
  • タンパク質サプリメント
  • ビタミンB12サプリメント
  • その他

第7章 北米のサルコペニア治療市場分析-流通チャンネル別

  • 薬局
  • 小売チャンネル
  • オンラインチャンネル
  • その他

第8章 北米のサルコペニア治療市場：国別分析

  • 北米
    • 米国
    • カナダ
    • メキシコ

第9章 サルコペニア治療市場-業界情勢

  • イントロダクション
  • サルコペニア治療市場における成長戦略
  • 無機的成長戦略
  • 有機的成長戦略

第10章 企業プロファイル

  • Abbott Laboratories
  • Bayer AG
  • Metagenics LLC
  • Nestle Health Science SA
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Amway Corp
  • GSK Plc
  • Makers Nutrition LLC

第11章 付録

図表

List Of Tables

  • Table 1. North America Sarcopenia Treatment Market Segmentation
  • Table 2. Sarcopenia Drug Under Clinical Development
  • Table 3. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030 (US$ Million) - By Treatment Type
  • Table 5. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Million) - By Distribution Channel
  • Table 6. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Country
  • Table 7. United States Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 8. United States Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 9. Canada Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 10. Canada Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 11. Mexico Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 12. Mexico Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 13. Recent Inorganic Growth Strategies in the Sarcopenia Treatment Market
  • Table 14. Recent Organic Growth Strategies in the Sarcopenia Treatment Market
  • Table 15. Glossary of Terms, Sarcopenia Treatment Market

List Of Figures

  • Figure 1. North America Sarcopenia Treatment Market Segmentation, By Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
  • Figure 4. North America Sarcopenia Treatment Market Share (%) - By Treatment Type, 2022 and 2030
  • Figure 5. Vitamin D and Calcium Supplement : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 6. Protein Supplement : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 7. Vitamin B12 Supplement: North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 8. Others : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 9. North America Sarcopenia Treatment Market Share (%) - By Distribution Channel, 2022 and 2030
  • Figure 10. Pharmacies : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 11. Retail Channels : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 12. Online Channels : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 13. Others : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 14. North America Sarcopenia Treatment Market Revenue, by Key Countries, (2022) (US$ Mn)
  • Figure 15. North America Sarcopenia Treatment Market Breakdown by Key Countries, 2022 and 2030 (%)
  • Figure 16. United States Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 17. Canada Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 18. Mexico Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 19. Growth Strategies in the Sarcopenia Treatment Market
目次
Product Code: BMIRE00030523

The North America sarcopenia treatment market was valued at US$ 1,451.12 million in 2022 and is expected to reach US$ 2,273.85 million by 2030; it is estimated to register a CAGR of 5.8% from 2022 to 2030.

Upsurge in Geriatric Population Fuels North America Sarcopenia Treatment Market

The geriatric population is prone to sarcopenia, orthopedic disorders, metabolic disorders, and neurological disorders, among others. Sarcopenia is a geriatric illness characterized by a progressive loss of the mass and strength of skeletal muscles. It is associated with a higher risk of unfavorable health outcomes, e.g., falls, disabilities, institutionalization, poor quality of life, and mortality. The elderly populace is rising rapidly in developed countries. According to the World Health Organization (WHO), the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. Also, according to the 2020 Census, the population of US 65 and older increased about five times faster than the total population during the 100 years between 1920 and 2020. In 2020, the number of older populations reached 55.8 million, or 16.8% of the total population of the US.

Aging results in a reduction in muscle mass as one of the major changes in body composition. A significant decline in food consumption among elderly people is one of the key factors causing the loss of muscle mass. According to the National Library of Medicine, people from the age group of 50-60 lose nearly 1.5% of muscle strength every year, while 1-2% of muscle mass is lost annually after the age of 60. Compared to general populations, elderly patients had a higher prevalence of sarcopenia. According to an article published in June 2023 in Elsevier, the prevalence of sarcopenia ranges from 18% in diabetic patients to 66% in those with incurable esophageal cancer. Hence, the rising elderly population contributes significantly to the sarcopenia treatment market growth.

North America Sarcopenia Treatment Market Overview

The sarcopenia treatment market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. The sarcopenia treatment market growth in North America is attributed to the rising adoption of nutraceutical supplements for the treatment. In addition, the surging prevalence of orthopedic disorders with the increasing number of cases of vitamin B12 and vitamin D deficiency in the geriatric population fuels the market in this region.

Sarcopenia prevalence varies with age and gender; elderly people residing in assisted living facilities or communities in the US are at a higher risk of developing this condition. According to the National Institute of Health, in 2019, the anticipated hospitalization cost for persons with sarcopenia in the US was US$ 40.4 billion. People with sarcopenia pay US$ 2,315 more for hospital visits than people with normal muscle mass and function every year on average; they are almost twice as likely to be hospitalized than people without sarcopenia. Additionally, a 10% decrease in the loss of skeletal muscle can prevent the possible comorbidity of sarcopenia and save around US$ 1 billion in annual US medical care expenses.

North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Sarcopenia Treatment Market Segmentation

The North America sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the North America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest North America sarcopenia treatment market share in 2022.

In terms of distribution channel, the North America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest North America sarcopenia treatment market share in 2022.

By country, the North America sarcopenia treatment market is segmented into the US, Canada, and Mexico. The US dominated the North America sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC are some of the leading companies operating in the North America sarcopenia treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Sarcopenia Treatment Market - Key Industry Dynamics

  • 4.1 North America Sarcopenia Treatment Market - Key Industry Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Upsurge in Geriatric Population
    • 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
  • 4.3 Key Market Restraints:
    • 4.3.1 Unavailability of Direct Interventions
  • 4.4 Key Market Opportunities:
    • 4.4.1 Products in Clinical Trial Phases
  • 4.5 Future Trends:
    • 4.5.1 Rising Awareness About Sarcopenia
  • 4.6 Impact of Drivers and Restraints:

5. Sarcopenia Treatment Market - North America Market Analysis

  • 5.1 North America Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
  • 5.2 North America Sarcopenia Treatment Market Forecast and Analysis

6. North America Sarcopenia Treatment Market Analysis - By Treatment Type

  • 6.1 Vitamin D and Calcium Supplement
    • 6.1.1 Overview
    • 6.1.2 Vitamin D and Calcium Supplement : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.2 Protein Supplement
    • 6.2.1 Overview
    • 6.2.2 Protein Supplement : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Vitamin B12 Supplement
    • 6.3.1 Overview
    • 6.3.2 Vitamin B12 Supplement: North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Others
    • 6.4.1 Overview
    • 6.4.2 Others : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)

7. North America Sarcopenia Treatment Market Analysis - By Distribution Channel

  • 7.1 Pharmacies
    • 7.1.1 Overview
    • 7.1.2 Pharmacies : North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Retail Channels
    • 7.2.1 Overview
    • 7.2.2 Retail Channels : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Online Channels
    • 7.3.1 Overview
    • 7.3.2 Online Channels : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others : North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

8. North America Sarcopenia Treatment Market - Country Analysis

  • 8.1 North America
    • 8.1.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
      • 8.1.1.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
      • 8.1.1.2 United States Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.2.1 United States Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.2.2 United States Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.3 Canada Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.3.1 Canada Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.3.2 Canada Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.4 Mexico Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.4.1 Mexico Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.4.2 Mexico Sarcopenia Treatment Market Breakdown by Distribution Channel

9. Sarcopenia Treatment Market-Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Sarcopenia Treatment Market
  • 9.3 Inorganic Growth Strategies
    • 9.3.1 Overview
  • 9.4 Organic Growth Strategies
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 Bayer AG
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 Metagenics LLC
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Nestle Health Science SA
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Novartis AG
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Pfizer Inc
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Sanofi SA
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Amway Corp
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 GSK Plc
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments
  • 10.10 Makers Nutrition LLC
    • 10.10.1 Key Facts
    • 10.10.2 Business Description
    • 10.10.3 Products and Services
    • 10.10.4 Financial Overview
    • 10.10.5 SWOT Analysis
    • 10.10.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners
  • 11.2 Glossary of Terms